CA-GLOBALLOGIC-INC.
11.1.2023 12:01:37 CET | Business Wire | Press release
GlobalLogic Inc., a Hitachi Group company and Digital Engineering leader, announced today that it has been named an overall Leader in the Zinnov Zones for ER&D Services 2022 Ratings. The report provides a 360-degree assessment of engineering research and development (ER&D) service providers, identifying their prowess and scalability across key markets and technologies. It is leveraged by company decision makers seeking to identify vetted service providers to support a wide range of engineering projects. Such resources are increasingly more important as investment in digital transformation rises rapidly across all industries to satisfy a growing demand for intelligent, connected, and data-driven experiences for consumers and company employees alike.
Zinnov is a global management consulting and strategy advisory firm with 20+ years of experience. As part of its annual ER&D Services Zinnov Zones ratings exercise, the company evaluates more than 50 global service providers across multiple verticals, micro-verticals, and geographies. GlobalLogic’s earned position as an overall leader indicates the digital engineering firm has demonstrated itself to be an Established, Expansive company when compared to its peers—labels specifically measuring:
- Established: proven specialization; R&D practice maturity (depth and maturity of services); innovation and IP; ecosystem linkages
- Expansive: scale and scalability; number of verticals serviced; client spread/diversification
Validating its overall leadership recognition, GlobalLogic was rated in the leadership zone for the following verticals and technologies:
- Automotive
- Consumer Software
- Data & AI Engineering
- Enterprise Software
- Experience Engineering
- Telecommunications
- Telehealth
The 2022 edition of the Zones ratings marks GlobalLogic’s seventh year earning a spot in the ER&D Services Ratings’ general leader quadrant, having first placed there in 2016. While GlobalLogic first moved to an overall leadership position three years ago, it has since moved up in its rating and earned higher leadership zone positions in several sub-categories listed above.
“The recognition received in the Zinnov Zones evaluation is a direct testament to the ingenuity, commitment, and skills displayed by our team members around the world,” said Arya Barirani, Chief Marketing Officer, GlobalLogic. “From our perspective, this rating acknowledges our continued ability to deepen our foothold in a wide variety of markets. It also acknowledges our dedication to broadening our experience in technologies that drive next- gen digital transformations. These investments in our people, training, and facilities are all designed to help us better serve our customers.”
Sidhant Rastogi, Managing Partner, Zinnov, said, “GlobalLogic’s intense focus on building new-age technology capabilities, combined with its digital accelerators and its self-contained innovation labs, has helped the firm drive high value transformation for its customers. GlobalLogic continues to strengthen its digital core through strategic acquisitions like Fortech, which has enabled it to expand its portfolio of offerings across technologies and geographies. A well-articulated growth strategy and a data-driven approach across its wide-spectrum of Digital Engineering Services offerings has helped GlobalLogic firmly anchor its leadership position in the 2022 Zinnov Zones ER&D ratings.”
The 2022 ER&D Services Ratings report as well as prior year reports can be found here: https://zinnovzones.com/ratings/e-r-and-d-services/overall/2022.
About Zinnov
Founded in 2002, Zinnov is a global management consulting and strategy advisory firm with a presence in New York, Santa Clara, Seattle, Houston, Bangalore, Gurgaon, Paris, and Pune. With a team of experienced consultants, subject matter experts, and research professionals, Zinnov has partnered with Global Enterprises, Fortune 2000 companies, Global System Integrators, and Private Equity firms across their value creation journeys to develop actionable insights – across revenue, talent, innovation, scale, and optimization. For more information, visit Zinnov.
About GlobalLogic
GlobalLogic (www.globallogic.com) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005241/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom